NCT02099058: A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors

NCT02099058
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Subject has known uncontrolled metastases to the central nervous system (CNS)
https://ClinicalTrials.gov/show/NCT02099058

Comments are closed.

Up ↑